Vivo Opportunity Fund Holdings, L.P. and affiliated entities filed Amendment No. 5 to a beneficial ownership statement with the SEC on November 16, 2026, disclosing a 9.99% position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) as of September 30, 2026.

Key Highlights

  • Filing date: November 16, 2026, covering an event date of September 30, 2026.
  • Vivo Opportunity Fund Holdings position: 3,911,375 shares of common stock reported as beneficially owned, representing 9.99% of the class.
  • Vivo Opportunity Cayman Fund position: 394,884 shares of common stock reported as beneficially owned, also representing 9.99% of the class.
  • Three convertible preferred series involved: Series A-3, Series A-4, and Series A-5 Convertible Preferred Stock, each underlying separate warrant tranches exercisable within 60 days of the statement.
  • Blocking provision: According to the filing, each preferred series contains a provision preventing conversion if it would result in the holder exceeding 9.99% of the issuer's voting securities; reported share counts do not reflect this limit.
  • Sole voting and dispositive power: All reported shares carry sole voting power and sole dispositive power, with zero shared voting or dispositive power for each reporting entity.

Vivo Opportunity Entities Detail Their Unicycive Preferred Stock Holdings

According to the filing, Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership, reported aggregate beneficial ownership of 3,911,375 shares of common stock in Unicycive Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered at 1975 W. El Camino Real, Suite 204, Mountain View, CA 94040. The figure encompasses three components: 1,162,841 shares issuable upon conversion of 627.934032 shares of Series A-3 Convertible Preferred Stock underlying Tranche A Warrants; 1,057,129 shares issuable upon conversion of 623.705756 shares of Series A-4 Convertible Preferred Stock underlying Tranche B Warrants; and 1,691,405 shares issuable upon conversion of 1,251.639330 shares of Series A-5 Convertible Preferred Stock underlying Tranche C Warrants. The filing notes that Vivo Opportunity, LLC serves as the general partner of Vivo Opportunity Fund Holdings, L.P., and both entities reported identical share counts and the same 9.99% ownership percentage.

A separate reporting entity, Vivo Opportunity Cayman Fund, L.P., organized in the Cayman Islands, reported beneficial ownership of 394,884 shares, comprising 117,398 shares from Series A-3 Preferred Stock underlying Tranche A Warrants, 106,725 shares from Series A-4 Preferred Stock underlying Tranche B Warrants, and 170,761 shares from Series A-5 Preferred Stock underlying Tranche C Warrants. Vivo Opportunity Cayman, LLC, also organized in the Cayman Islands, is the general partner of this fund and reported the same 394,884-share position. The filing states that all securities are held of record by each respective fund entity. The reported amounts, the filing explains, do not give effect to the blocking provisions embedded in each preferred series, which cap actual conversion at 9.99% of the issuer's voting securities.

What Was Disclosed

Four affiliated Vivo Opportunity entities filed Amendment No. 5 to their beneficial ownership statement covering Unicycive Therapeutics common stock. The positions are composed entirely of shares issuable upon conversion of three series of convertible preferred stock through warrant tranches, subject to a 9.99% conversion cap per the filing.